- Home
- FURY vs IPA Comparison
FURY vs IPA Comparison
Compare FURY & IPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FURY
- IPA
- Stock Information
- Founded
- FURY 2008
- IPA 1983
- Country
- FURY Canada
- IPA United States
- Employees
- FURY N/A
- IPA N/A
- Industry
- FURY Precious Metals
- IPA Biotechnology: Pharmaceutical Preparations
- Sector
- FURY Basic Materials
- IPA Health Care
- Exchange
- FURY Nasdaq
- IPA Nasdaq
- Market Cap
- FURY 94.8M
- IPA 98.9M
- IPO Year
- FURY N/A
- IPA 2017
- Fundamental
- Price
- FURY $0.52
- IPA $1.73
- Analyst Decision
- FURY Strong Buy
- IPA Strong Buy
- Analyst Count
- FURY 1
- IPA 2
- Target Price
- FURY $1.40
- IPA $4.00
- AVG Volume (30 Days)
- FURY 223.4K
- IPA 2.3M
- Earning Date
- FURY 08-11-2025
- IPA 07-29-2025
- Dividend Yield
- FURY N/A
- IPA N/A
- EPS Growth
- FURY N/A
- IPA N/A
- EPS
- FURY N/A
- IPA N/A
- Revenue
- FURY N/A
- IPA $17,744,713.00
- Revenue This Year
- FURY N/A
- IPA $4.67
- Revenue Next Year
- FURY N/A
- IPA $14.15
- P/E Ratio
- FURY N/A
- IPA N/A
- Revenue Growth
- FURY N/A
- IPA 0.01
- 52 Week Low
- FURY $0.35
- IPA $0.27
- 52 Week High
- FURY $0.59
- IPA $2.41
- Technical
- Relative Strength Index (RSI)
- FURY 50.91
- IPA 53.58
- Support Level
- FURY $0.54
- IPA $1.61
- Resistance Level
- FURY $0.58
- IPA $2.41
- Average True Range (ATR)
- FURY 0.02
- IPA 0.31
- MACD
- FURY -0.00
- IPA -0.02
- Stochastic Oscillator
- FURY 30.78
- IPA 27.89
About FURY Fury Gold Mines Limited
Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.
About IPA ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd is a techbio company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. IPA has several subsidiaries in North America and Europe.